Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | MST1R | Q04912 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953806 | 0.86 | ALOX5 (0.54) | ALOX5ALDH1A1LMNARAB9AMAPT | |
| SCHEMBL1359017 | 0.84 | ALOX5 (0.55) | ALOX5ALDH1A1LMNARAB9AMAPT | |
| SCHEMBL10685900 | 0.82 | LMNA (0.53) | ALOX5ALDH1A1LMNAL3MBTL1RAB9A | |
| SCHEMBL3993398 | 0.82 | LMNA (0.61) | ALDH1A1LMNAL3MBTL1RAB9AMAPT | |
| SCHEMBL14816245 | 0.80 | KDM4E (0.60) | ALOX5ALDH1A1LMNARAB9AMAPT | |
| SCHEMBL4951421 | 0.79 | ALDH1A1 (0.53) | ALOX5ALDH1A1LMNARAB9AMAPT | |
| Ethyl Acetate SCHEMBL27619292 | 0.79 | ALDH1A1 (0.54) | ALOX5ALDH1A1LMNARAB9AMAPT | |
| SCHEMBL827308 | 0.78 | ALDH1A1 (0.61) | ALDH1A1RAB9AMAPTMETSRC | |
| SCHEMBL4954671 | 0.78 | ALDH1A1 (0.55) | ALOX5ALDH1A1LMNARAB9AMAPT | |
| SCHEMBL27838094 | 0.78 | ALOX5 (0.57) | ALOX5ALDH1A1LMNARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1313716-B1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1313716-B1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20050245584-A1 | Peroxisome proliferator activated receptor agonists | BROOKS DAWN A | 2005-11-03 | — | — | US | disclosed |
| US-6930120-B2 | Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists | ELI LILLY AND COMPANY (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040097590-A1 | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists | BROOKS DAWN ALISA (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1313716-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016331-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097590-A1 | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists | PPARA, PPARG, PPARD | ALOX5 561/4885ALDH1A1 470/4885LMNA 3429/4885 |
| US-20050245584-A1 | Peroxisome proliferator activated receptor agonists | PPARG, PPARA, PPARD | ALOX5 733/4885ALDH1A1 1612/4885LMNA 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.